CD27-TF tag mRNA-LNP

CD27 is encoded by the CD27 gene and is a member of the tumor necrosis factor receptor superfamily. This receptor is required for the generation and long-term maintenance of T cell immunity. Through binding to the ligand CD70, CD27 plays a key role in regulating B cell activation and immunoglobulin synthesis and transduces signals leading to the activation of NF-κB and MAPK8/JNK. Under physiological conditions, the expression of CD70 and CD27 is tightly controlled in costimulatory immune responses. CD70 and CD27 are aberrantly expressed in many hematological and solid malignancies, promoting malignant stemness, proliferation and survival. Dysregulation of the CD70-CD27 axis within the tumor and its microenvironment is associated with tumor progression and immunosuppression. Varlilumab, an agonist IgG1 antibody against CD27, stimulates CD27 signaling and appears to stimulate T cells and increase production of cytokines such as IFNγ. As a drug, Varlilumab is in early clinical trials for certain cancers.
This product is designed as a tool for the delivery and expression of human TF tagged CD27 mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of CD27-TF mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The CD27-TF fusion protein is approximately 34 kD, consisting of CD27 (291 amino acids) and a C-terminal TF tag (15 amino acids). The GenPept accession number for CD27 is NP_001400192.